Ziihera

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. The company's lead product, Ziihera (zanidatamab), is a bispecific antibody targeting HER2 that recently received FDA accelerated approval for previously treated HER2-amplified biliary tract cancer. Zymeworks utilizes a suite of proprietary technology platforms, including Azymetric and ZymeLink, to engineer antibodies and antibody-drug conjugates with enhanced therapeutic profiles. Beyond its lead program, the company maintains a robust pipeline of candidates targeting various solid tumors, often through strategic partnerships with major pharmaceutical firms like Jazz Pharmaceuticals and BeiGene.